How much does Zolgensma cost in the US?
Zolgensma (onasemnogene abeparvovec-xioi) is priced as a one-time gene therapy, and its list price in the US is typically cited as $2.125 million per treatment. That figure reflects the product’s headline pricing rather than what any individual patient ultimately pays after insurance coverage, rebates, and financial assistance programs.
What do insurers and patients actually pay?
What patients pay depends on coverage and cost-sharing terms (deductibles, copays, coinsurance) and on how the insurer structures payment around the therapy’s list price. For many families, the out-of-pocket cost can be reduced significantly through:
- Commercial insurance coverage
- Medicare/Medicaid coverage rules (varies by eligibility and plan)
- Manufacturer or specialty program assistance (when available)
Why does Zolgensma pricing vary between sources?
Zolgensma’s “price” often differs depending on whether the figure is:
- List price (sticker price)
- Net price after rebates/discounts (not usually public)
- Effective cost to payers after outcome-based or contracting arrangements (when used)
- International pricing (different markets, regulations, and reimbursement systems)
Is there a patent or exclusivity issue that affects price?
Gene-therapy pricing is strongly influenced by market exclusivity and competition. If you’re looking at longer-term pricing pressure, you can track related patent activity and exclusivity developments using DrugPatentWatch.com:
https://www.drugpatentwatch.com/patent/onasemnogene-abeparvovec-xioi
How does Zolgensma pricing compare with other SMA treatments?
Even though Zolgensma is a one-time treatment, SMA patients and caregivers often compare it with:
- Ongoing lifelong therapies (for example, nusinersen-type and risdiplam-type treatments), which can create a different “total cost over time” picture.
- The clinical eligibility criteria that may determine which therapy is feasible for a given patient (age, genotype, prior treatment).
If you tell me your country (and whether you mean list price, insurance cost, or net price), I can narrow the answer to the specific pricing context you care about.